Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29881751 | 1.00 | HTR1A (0.51) | HTR1ASLC6A2SLC6A3SLC6A4KDM4E | |
| SCHEMBL7502997 | 0.90 | SLC2A1 (0.51) | HTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL16354172 | 0.88 | KDM4E (0.46) | HTR1ASLC6A4KDM4EALDH1A1KDM4C | |
| SCHEMBL29880647 | 0.85 | HTR1A (0.49) | HTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL1893297 | 0.85 | HTR1A (0.49) | HTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL2704956 | 0.85 | SLC6A2 (0.57) | HTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL29880731 | 0.85 | HTR1A (0.53) | HTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL1889888 | 0.85 | HTR1A (0.53) | HTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL16569423 | 0.84 | — | — | |
| SCHEMBL1885142 | 0.81 | HTR1A (0.55) | HTR1ASLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262785-B1 | BENZOFURANE DERIVATIVES AS FXR MODULATORS | MERCK PATENT GMBH (DE) | 2015-01-14 | — | — | EP | claimed |
| US-8575161-B2 | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators | MERCK PATENT GMBH (DE) | 2013-11-05 | — | — | US | claimed |
| US-20110105475-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | MERXCK PATENT GESELLSCHAFT (DE) | 2011-05-05 | — | — | US | claimed |
| EP-2262785-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | Merck Patent GmbH (DE) | 2010-12-22 | — | — | EP | claimed |
| WO-2009127321-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | MERCK PATENT GMBH, (DE) | 2009-10-22 | — | — | WO | claimed |
| EP-2110374-A1 | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators | Merck Sante (FR) | 2009-10-21 | — | — | EP | claimed |
| EP-3711762-A1 | A FARNESOID X RECEPTOR AGONSITS FORUSE AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-09-23 | — | — | EP | disclosed |
| US-10071108-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-11 | — | — | US | disclosed |
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-06-21 | — | — | US | disclosed |
| US-9895380-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-02-20 | — | — | US | disclosed |
| US-20160220586-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-08-04 | — | — | US | disclosed |
| EP-2262785-B1 | BENZOFURANE DERIVATIVES AS FXR MODULATORS | MERCK PATENT GMBH (DE) | 2015-01-14 | — | — | EP | disclosed |
| US-8575161-B2 | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators | MERCK PATENT GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20110105475-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | MERXCK PATENT GESELLSCHAFT (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2110374-A1 | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators | Merck Sante (FR) | 2009-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, FXR2, FXR1 | HTR1A 3206/4885SLC6A2 2686/4885SLC6A3 3456/4885 |
| US-20160220586-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, NR1H3, FXR2 | HTR1A 3218/4885SLC6A2 2787/4885SLC6A3 3537/4885 |
| US-20110105475-A1 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS | FXR1, FXR2, NR1H4 | HTR1A 1570/4885SLC6A2 1721/4885SLC6A3 1576/4885 |
| US-10071108-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection | NR1H4, FXR2, FXR1 | HTR1A 3206/4885SLC6A2 2686/4885SLC6A3 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.